Everolimus also induced a modest decrease in tumor growth, size and proliferation of androgen sensitive (Fig. 3A–D) and castrate resistant Myc-CaP tumors (Fig. 3E–H), while panobinostat/everolimus combination therapy significantly reduced tumor proliferation and volume in both Myc-CaP/AS (Fig. 3A–D) and Myc-CaP/CR (Fig. 3E–H) tumor models. Here, MYC is linked to neoplasm.